Inhaled tuberculosis booster vaccine initiates Phase I clinical trial in Indonesia and completes first subject enrollment.
November 14, 2025
Source: drugdu
69
People's Finance News, November 13th - CanSino Biologics(688185) announced on November 13 that its inhaled tuberculosis vaccine (adenovirus type 5 vector) (hereinafter referred to as "inhaled tuberculosis booster vaccine") recently started Phase I clinical trials in Indonesia and completed the enrollment of the first subject in Phase I clinical trials.
https://finance.eastmoney.com/a/202511133563746120.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
